CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target

Positive
AI Analysis

Summary

Barclays initiated coverage of Sutro Biopharma with an Overweight rating and $56 price target.

Importance:3/10
Sentiment:
0.60
analyst_ratingprice_targetequity_research
Related Companies

Read the original article

Published by yahoo_finance on May 28, 2026 11:24 AM

Read Original